AR095977A1 - Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína - Google Patents
Un procedimiento para aumentar la formación de ácido piroglutámico de una proteínaInfo
- Publication number
- AR095977A1 AR095977A1 ARP140101455A ARP140101455A AR095977A1 AR 095977 A1 AR095977 A1 AR 095977A1 AR P140101455 A ARP140101455 A AR P140101455A AR P140101455 A ARP140101455 A AR P140101455A AR 095977 A1 AR095977 A1 AR 095977A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- procedure
- formation
- increase
- pyroglutamic acid
- Prior art date
Links
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 title abstract 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 title abstract 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un procedimiento para la conversión de un residuo de glutamina y/o ácido glutámico N-terminal de una proteína en ácido piroglutámico en un procedimiento de purificación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13162241 | 2013-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095977A1 true AR095977A1 (es) | 2015-11-25 |
Family
ID=48044678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101455A AR095977A1 (es) | 2013-04-04 | 2014-04-01 | Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10400042B2 (es) |
| EP (1) | EP2981553A1 (es) |
| JP (1) | JP2016523812A (es) |
| KR (1) | KR20150138273A (es) |
| CN (1) | CN105121469A (es) |
| AR (1) | AR095977A1 (es) |
| AU (1) | AU2014247034B2 (es) |
| BR (1) | BR112015025106A2 (es) |
| CA (1) | CA2907766A1 (es) |
| EC (1) | ECSP15043422A (es) |
| HK (1) | HK1221472A1 (es) |
| MX (1) | MX2015014038A (es) |
| RU (1) | RU2015147187A (es) |
| SA (1) | SA515361251B1 (es) |
| SG (2) | SG10201708088WA (es) |
| TW (1) | TW201444863A (es) |
| UY (1) | UY35517A (es) |
| WO (1) | WO2014161940A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034776B1 (ru) | 2015-05-20 | 2020-03-19 | Эмджен Инк. | Триазоловые агонисты рецептора apj |
| US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| JOP20190100A1 (ar) * | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
| WO2019043096A1 (en) * | 2017-08-30 | 2019-03-07 | Fresenius Kabi Deutschland Gmbh | METHOD FOR PURIFYING IL-6 ANTI-RECEPTOR ANTIBODIES |
| US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| EP3643322A1 (en) * | 2018-10-26 | 2020-04-29 | Mabion SA | Low aggregate anti cd20 ligand formulation |
| CN112110983A (zh) * | 2019-06-21 | 2020-12-22 | 正大天晴药业集团股份有限公司 | 蛋白质的纯化方法 |
| CN112725398B (zh) * | 2019-10-29 | 2022-07-01 | 中国食品发酵工业研究院有限公司 | 一种具有辅助降血糖功能的豌豆肽及其制备方法 |
| US11598116B1 (en) | 2020-10-01 | 2023-03-07 | Florida Aluminum Systems, Llc | Mounting system for separating and connecting fencing slabs |
| HUP2400216A1 (hu) * | 2024-04-17 | 2025-10-28 | Richter Gedeon Nyrt | N-terminális glutamint tartalmazó immunglobulinok tisztítására szolgáló eljárások |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| ATE506433T1 (de) | 2003-12-19 | 2011-05-15 | Novo Nordisk As | Prozessierung von peptiden und proteinen |
| US20060286629A1 (en) * | 2003-12-19 | 2006-12-21 | Norby Inga S N | Processing of Peptides and Proteins |
| EP1787126B1 (en) | 2004-07-20 | 2009-09-23 | Symphogen A/S | A procedure for characterization of a polyclonal cell line |
| US20080312425A1 (en) * | 2004-08-30 | 2008-12-18 | Lonza Biologics Plc. | Ion Exchange Chromatography and Purification of Antibodies |
| WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| MX2010004740A (es) * | 2007-10-30 | 2010-05-27 | Genentech Inc | Purificacion de anticuerpos por cromatografia de intercambio cationico. |
| WO2010138184A2 (en) | 2009-05-27 | 2010-12-02 | Synageva Biopharma Corp. | Avian derived antibodies |
| CN102492040B (zh) | 2011-12-29 | 2014-06-25 | 嘉和生物药业有限公司 | 一种抗her2或/和抗her3抗体蛋白的纯化方法 |
-
2014
- 2014-03-31 UY UY0001035517A patent/UY35517A/es not_active Application Discontinuation
- 2014-04-01 AR ARP140101455A patent/AR095977A1/es unknown
- 2014-04-02 TW TW103112224A patent/TW201444863A/zh unknown
- 2014-04-03 CA CA2907766A patent/CA2907766A1/en not_active Abandoned
- 2014-04-03 AU AU2014247034A patent/AU2014247034B2/en not_active Expired - Fee Related
- 2014-04-03 MX MX2015014038A patent/MX2015014038A/es unknown
- 2014-04-03 JP JP2016505823A patent/JP2016523812A/ja active Pending
- 2014-04-03 CN CN201480019372.7A patent/CN105121469A/zh active Pending
- 2014-04-03 BR BR112015025106A patent/BR112015025106A2/pt not_active IP Right Cessation
- 2014-04-03 HK HK16109481.9A patent/HK1221472A1/zh unknown
- 2014-04-03 WO PCT/EP2014/056700 patent/WO2014161940A1/en not_active Ceased
- 2014-04-03 KR KR1020157030512A patent/KR20150138273A/ko not_active Withdrawn
- 2014-04-03 EP EP14718533.4A patent/EP2981553A1/en not_active Ceased
- 2014-04-03 SG SG10201708088WA patent/SG10201708088WA/en unknown
- 2014-04-03 SG SG11201507815XA patent/SG11201507815XA/en unknown
- 2014-04-03 RU RU2015147187A patent/RU2015147187A/ru not_active Application Discontinuation
- 2014-04-03 US US14/780,964 patent/US10400042B2/en active Active
-
2015
- 2015-10-01 SA SA515361251A patent/SA515361251B1/ar unknown
- 2015-10-14 EC ECIEPI201543422A patent/ECSP15043422A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014161940A1 (en) | 2014-10-09 |
| JP2016523812A (ja) | 2016-08-12 |
| TW201444863A (zh) | 2014-12-01 |
| MX2015014038A (es) | 2016-06-02 |
| BR112015025106A2 (pt) | 2017-10-10 |
| CA2907766A1 (en) | 2014-10-09 |
| US10400042B2 (en) | 2019-09-03 |
| SA515361251B1 (ar) | 2018-07-01 |
| RU2015147187A (ru) | 2017-05-23 |
| SG11201507815XA (en) | 2015-10-29 |
| SG10201708088WA (en) | 2017-10-30 |
| EP2981553A1 (en) | 2016-02-10 |
| AU2014247034A1 (en) | 2015-10-01 |
| AU2014247034B2 (en) | 2018-08-23 |
| UY35517A (es) | 2014-10-31 |
| US20160060349A1 (en) | 2016-03-03 |
| RU2015147187A3 (es) | 2018-02-28 |
| KR20150138273A (ko) | 2015-12-09 |
| HK1221472A1 (zh) | 2017-06-02 |
| CN105121469A (zh) | 2015-12-02 |
| ECSP15043422A (es) | 2017-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095977A1 (es) | Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína | |
| NZ704662A (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
| CY1120646T1 (el) | Προγονικα κυτταρα μεσοδερμικης προελευσης | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| UY34675A (es) | ?proceso y aparato para tratar superficies de metal?. | |
| EA201792613A1 (ru) | Модуляторы cot и способы их применения | |
| GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| MX2022011225A (es) | Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif. | |
| EA201690280A1 (ru) | Композиции и способы, относящиеся к выделенным эндофитам | |
| MX2015006324A (es) | Metodos para la fabricacion de polipeptidos proteoliticamente procesados. | |
| EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
| MX375524B (es) | Anticuerpos anti-axl. | |
| EA202091397A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
| MX2015006915A (es) | Preparacion de una bebida estable. | |
| EA201600429A1 (ru) | Способ очистки 2,5-дихлорфенола | |
| EA201600026A1 (ru) | Бактериальная гиалуронидаза и способ ее производства | |
| IN2014MU00455A (es) | ||
| MX390924B (es) | Detergentes y agentes de limpieza que comprenden una combinación de amilasa y proteasa. | |
| UY34640A (es) | Proceso para preparar cemento, morteros y composiciones, con tratamiento de ultrafinos, y composiciones, productos de cemento, y aplicaciones. | |
| EA201690856A1 (ru) | Применение жирной кислоты таллового масла в связывании токсинов | |
| CL2017001383A1 (es) | Proceso para la fabricación de anhídrido carboxílico | |
| MX384260B (es) | Proceso para la preparacion de 3,7-dimetilnonan-1-ol. | |
| IN2013MU01290A (es) | ||
| UY34802A (es) | ?suspensión acuosa que contiene polímeros adsorbibles sostenibles, un proceso para prepararla y su uso?. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |